Treatment of non-Hodgkin lymphoma with point-of-care manufactured CAR T cells: a dual institution, phase 1 trialResearch in context

Treatment of non-Hodgkin lymphoma with point-of-care manufactured CAR T cells: a dual institution, phase 1 trialResearch in context

Summary: Background: Point-of-care manufacture of chimeric antigen receptor (CAR)-T cells can significantly reduce the time from apheresis to infusion. We conducted a dual-institution phase I trial aimed evaluating the safety and feasibility of this manufacturing model. Methods: CASE 2417 was a pha...

Full description

Saved in:
Bibliographic Details
Main Authors: Armin Ghobadi, Paolo F. Caimi, Jane S. Reese, Krishna Goparaju, Martina di Trani, Julie Ritchey, Zachary Jackson, Benjamin Tomlinson, Jennifer M. Schiavone, Sarah Kleinsorge-Block, Kayla Zamborsky, Linda Eissenberg, Dina Schneider, Kirsten M. Boughan, Emily C. Zabor, Leland Metheny, Molly Gallogly, Winfried Kruger, Michael Kadan, Andrew Worden A.S, Ashish Sharma, Brenda W. Cooper, Folashade Otegbeye, Rafick P. Sekaly, David N. Wald, Carmelo Carlo-Stella, John DiPersio, Rimas Orentas, Boro Dropulic, Marcos de Lima
Format: Article
Language:English
Published: Elsevier 2025-03-01
Series:EClinicalMedicine
Subjects:
Lymphoma
Chimeric antigen receptor T cell
Point-of-care manufacture
Immune effector cell therapy
Phase I
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537025000707
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2589537025000707

Similar Items